Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors

G Mantovani¹, D Treppiedi¹, E Giardino¹, R Catalano¹,², F Mangili¹, P Vercesi¹, M Arosio¹, A Spada¹ and E Peverelli¹

¹Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
²PhD Program in Endocrinological Sciences, Sapienza University of Rome, Rome, Italy

Correspondence should be addressed to G Mantovani: giovanna.mantovani@unimi.it

Abstract

Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.

Introduction

Pituitary tumors, accounting for 16.2% of all primary brain and other central nervous system tumors (Ostrom et al. 2017), are classified based on their secretory activity in non-functioning pituitary tumors (NFPTs) or hormone-secreting tumors, including prolactin (PRL)-, growth hormone (GH)- and adenocorticotropic hormone (ACTH)-secreting tumors. The 4th edition of the World Health Organization (WHO) classification of endocrine tumors (Lloyd et al. 2017) has adopted an adenohypophyseal cell lineage designation, with subsequent categorization of histological variants according to hormone content and the expression of pituitary-specific transcription factors.

Therapy is aimed to remove or reduce tumor mass and to normalize hormone secretion. Transsphenoidal surgery is the first choice of treatment in many cases. However, incomplete tumor resection and high rate of recurrence are associated with pituitary tumors invasion into surrounding tissues, a feature found in 30–50% of the lesions (Meiji et al. 2002). For PRL-secreting tumors, dopamine receptor type 2 (DRD2) agonists represent the first-line therapy, whereas somatostatin analogs (SSAs) are used for the pharmacological treatment of GH- and ACTH-secreting tumors. However, a variable percentage of patients (about 10% of PRL-, 30% of GH-, 50–70% of ACTH-secreting tumors) is resistant to these drugs.

Key Words

- filamin A
- cofilin
- somatostatin receptor 2
- dopamine receptor type 2
- pituitary tumors
Little is known about the molecular determinants underlying the local invasiveness and the pharmacological resistance of pituitary tumors. However, cytoskeleton involvement in both these critical issues has been recently demonstrated by several studies.

**Cell cytoskeleton and pituitary tumors: old and new players**

Cell cytoskeleton is a complex, dynamic and multifunctional network of protein filaments that can be classified in three main types: microfilaments, intermediate filaments and microtubules, originating by polymerization of different protein subunits. Microfilaments are composed by actin, intermediate filaments mainly by vimentin and keratin and microtubules by tubulin. They are characterized by different structural and physical properties, enabling specific cellular functions. In addition to provide and maintain cell shape and structure, they participate in a variety of cellular processes. In particular, microfilaments are involved in cell movement, shape, differentiation, division and intracellular transport, these activities being regulated by specific interactions with a variety of actin-binding proteins. Intermediate filaments participate in cell–cell and cell–matrix junctions. Microtubules are involved in mitosis, organelles transport and cell shape. In addition, these three types of filaments interact both directly, by physical contact, and indirectly, via biochemical signaling and gene transcription, allowing reciprocal regulation.

A cytoskeleton involvement in secretory granules’ transport and exocytosis in anterior pituitary cells has been demonstrated by electron microscopy techniques. Both actin filaments (Ostlund et al. 1977, Senda et al. 1989) and microtubules (Labrie et al. 1973, Sherline et al. 1977) bind anterior pituitary secretory granules in vitro, playing a role in their intracellular transport, approach to the plasma membrane and release. Moreover, agents that disrupt microtubules, such as colchicine or vinblastine, inhibited the transport of GH storage granules from the Golgi complex to the cytoplasmic pool (Howell & Tyhurst 1978).

Specific cytoskeleton features have been associated to pituitary tumors clinical behavior. Cytokeratins, components of the intermediate filaments, that are expressed in both normal and tumoral anterior pituitary (Halliday et al. 1990) are specific histological markers that designate different subtypes of GH-secreting pituitary tumors. In particular, densely granulated tumors are defined by perinuclear cytokeratin distribution, whereas sparsely granulated tumors are characterized by dot-like keratin immunoreactivity, commonly referred to as fibrous bodies. Histological subtype of the tumor correlates with the expression of SS receptor type 2 (SSTR2) and response to SSA (Brzana et al. 2013, Chinezu et al. 2014, Kiseljak-Vassiliades et al. 2015), but to date, the molecular mechanisms involved are unknown.

Regarding actin-binding proteins, a role in regulating migration and invasion of pituitary adenomas has been attributed to fascin, which organizes actin filaments in parallel bundles (Liu et al. 2016). The authors demonstrated that silencing of fascin in GH3 cells reduced cell invasion, with a mechanism involving NOTCH1/DLL pathway. They also found an association between fascin expression and invasion and increased risk of recurrence in NFPT and GH-secreting tumors.

In the last years, two major actin-binding proteins, filamin A (FLNA) and coflin, emerged as important players in the regulation of the complex intracellular processes that dictate pituitary tumors drug responsiveness and invasiveness. They participate in actin filaments crosslinking and remodeling, respectively, and in mediating SS and DA receptors intracellular effects.

**FLNA: structure and function**

Filamins (FLNs) are high-molecular-weight homodimeric actin-binding proteins which cross-link actin cytoskeleton filaments. FLNs family includes three homologous proteins, FLNA, B and C, encoded by different genes located on chromosome X, 3 and 7, respectively (van der Flier & Sonnenberg 2001). While FLNC is primarily expressed in cardiac, smooth and striated muscle, FLNA and B are both ubiquitously expressed, but FLNA is the most abundant isoform (Feng & Walsh 2004).

A complete loss of FLNA expression in mice causes embryonic lethality, cardiac malformations and skeletal defects (Hart et al. 2006). In humans, FLNA mutations lead to a broad spectrum of clinical disorders, called filaminopathies, which can be classified in loss of function or gain of function. FLNA loss-of-function mutations, leading to reduced or absent FLNA expression, are embryonic lethal in males but are manifest in females as periventricular nodular heterotopia (PVNH), a localized neuronal migration disorder during late embryonic and early fetal development, Ehlers–Danlos syndrome-like collagenopathy, macrothrombocytopenia and X-linked cardiac valvular dystrophy (XCVD) (Fox et al. 1998, Sheen...
et al. 2005, Bernstein et al. 2011, Ieda et al. 2018). FLNA variants can also present with seizures, cardiovascular and pulmonary findings (Robertson 2005).

In contrast, gain-of-function mutations of FLNA cause various skeletal dysplasias and congenital malformations affecting brain, viscera and urogenital tract (ototopadigital syndromes, frontometaphyseal dysplasia and Melnick–Needles syndrome) (Robertson et al. 2003, Robertson 2005), strongly suggesting a FLNA role in modulating signaling during organogenesis in multiple tissues.

The structure of a FLNA monomer is represented in Fig. 1. FLNA was originally discovered as an actin-crosslinking protein (Hartwig & Stossel 1975), a function derived from its ability to homodimerize in V-shaped flexible structures that cross-link perpendicular actin filaments, conferring membrane integrity and defending cells against mechanical stress. Moreover, the binding of FLNA with several transmembrane proteins, including channels and receptors, anchors actin cytoskeleton to the cell membrane. Besides these structural functions, mounting evidence suggests a major role of FLNA in signal transduction, due to its ability to bind a huge number of intracellular signaling molecules, kinases and transcription factors (Stossel et al. 2001, Nakamura et al. 2011). FLNA is implicated in the regulation and integration of multiple cellular processes, including cell adhesion, migration, maintenance of cell shape, differentiation, proliferation and transcription. Moreover, in different human tumors, FLNA may play opposite roles in regulating growth, invasion and metastasis (Shao et al. 2016).

FLNA functions are tightly regulated by several mechanisms, including FLNA phosphorylation, mechanical force, intramolecular inhibition, competition with other molecules and proteolysis, as discussed in ‘Mechanisms regulating FLNA expression and function in pituitary tumors’ section.

Cofilin: structure and function

The ADF/cofilin family is a key regulator of actin dynamics. It includes cofilin 1 (a non-muscle type of cofilin), cofilin 2 (a muscle type of cofilin) and ADF (actin-depolymerizing factor or destrin). Cofilin 1 (hereafter referred to as cofilin) is the most abundant and ubiquitous member of this family. Deletion of the cofilin gene CFL1 is embryonic lethal in mice owing to defects in proliferation, polarization and migration of neural crest cells (Gurniak et al. 2005, Bellenchi et al. 2007).

Cofilin is a small protein of 19 kDa composed of one actin-depolymerizing factor homology (ADF-H) domain and able to bind both globular (G) actin and filamentous (F) actin. It also contains a NLS that confers to cofilin the ability to carry G-actin to nucleus (Abe et al. 1993, Pendleton et al. 2003), where it regulates chromosome organization and gene activity (Percipalle 2013).

Cofilin exerts two major biochemical functions: first, it depolymerizes ADP-bound actin filaments near the pointed ends to supply a pool of free G-actin monomers for polymerization; second, it severs actin filaments and initiates actin polymerization by increasing the number of actin-free barbed ends, from which F-actin polymerizes (Bravo-Cordero et al. 2013).

Since actin cytoskeleton reorganization is crucial for a number of cellular processes, it is not surprising that cofilin activity is tightly regulated. The main mechanism regulating cofilin activity is phosphorylation at Ser3 (Agnew et al. 1995), that prevents its ability to bind actin. Small GTPases of the Rho family are able to promote this posttranslational modification, by triggering a cascade of kinases, including PAK and ROCK, that activate LIMK1 and LIMK2, which ultimately target cofilin. On the other hand, cofilin is dephosphorylated by different phosphatases, such as slingshot 1L, chronophin and phosphatases type 1, 2A and 2B. Even though phosphorylated cofilin (P-cofilin) is generally considered the inactive form of cofilin, it can exert specific functions, such as to promote

![Figure 1](https://erc.bioscientifica.com)

**Figure 1**

Schematic representation of a FLNA. A FLNA monomer is composed of 2647 amino acids and weights 280 kDa. At the N-terminus there is an actin-binding domain that consists of two calponin homology domains, followed by 24 immunoglobulin (Ig)-like β-sandwich fold repeats of about 96 aminoacidic residues each. Repeats 1–15 (rod-1 domain) and 16–23 (rod-2 domain) are separated by a flexible hinge region (H1), and another hinge (H2) separates repeats 23 and 24. FLNA can be cleaved by calpain at (rod-2 domain) are separated by a flexible hinge region (H1), and another hinge (H2) separates repeats 23 and 24. FLNA can be cleaved by calpain at both H1 and H2. Repeat 24 is the self-association domain that mediates FLNA homodimerization. A secondary actin-binding domain of lower affinity is located in the rod-1 domain, whereas rod-2 does not interact with actin filaments, remaining free for interactions with multiple partner proteins. Indeed, the majority of FLNA interactions with receptors and signaling proteins are mediated by repeats 16–24. Repeats interacting with DRD2 and SST2, as well as FLNA scaffold region, are shown. Repeat 20 contains a putative nuclear localization signal (NLS) and the residue serine 2152 target of PKA phosphorylation. The deletion of 41 amino acids between repeat 19 and 20, present in the splice variant var-1 of FLNA, is indicated.
the translocation of phospholipase D1 to the plasma membrane and to stimulate its activity (Han et al. 2007). Beside phosphorylation, that remains the most important and the most studied system of cofilin regulation, other mechanisms have been described, such as cofilin ubiquitination, pH alterations, oxidation, binding to PtdIns(4,5)P₂ or to tropomyosins, cortactin, CAP1/Srv2p, coronins and Aip1 (Bernstein & Bamburg 2010), that might contribute to finely tune cofilin activity.

Cofilin has been demonstrated to be involved in cancer development, progression, invasion and metastasis. Both an increase of cofilin expression and a reduction of cofilin phosphorylation has been found in human malignant cells, suggesting its potential use as diagnostic/prognostic tumor biomarker (reviewed in Shishkin et al. 2016).

**Cytoskeleton role in pituitary tumors drug responsiveness**

**FLNA role in PRL-secreting tumors responsiveness to DRD2 agonists**

FLNA involvement in DRD2 regulation is well established. FLNA repeat 19 directly binds DRD2 third intracellular loop (Lin et al. 2001), with a strong impact on DRD2 coupling to adenylate cyclase, receptor clustering and expression on the plasma membrane in human melanoma cells (Li et al. 2000, Lin et al. 2002) (Fig. 1).

Concerning PRL-secreting pituitary tumors, Peverelli et al. showed that the presence of FLNA is essential for DRD2 expression and intracellular transduction of dopamine inhibitory signals (Peverelli et al. 2012). The authors demonstrated that tumor tissues from patients resistant to DRD2 agonists treatment showed a reduced expression of both DRD2 and FLNA, by both immunohistochemistry and Western blot. Moreover, they showed by in vitro experiments that the absence of FLNA caused the loss of DRD2. Indeed, FLNA gene silencing or overexpression in primary cultured prolactinoma cells from drug-sensitive or -resistant tumors produced corresponding decrease or increase, respectively, of DRD2 (Peverelli et al. 2012). The molecular mechanism involved has been elucidated in MMQ, a rat cell model of prolactinoma endogenously expressing functional DRD2 and FLNA. In these cells, FLNA was required for both DRD2 targeting to the cell membrane and DRD2 protection against lysosomal degradation (Peverelli et al. 2012) (Fig. 2). In agreement

---

**Figure 2**

The figure schematically represents the proposed model of cytoskeleton involvement in regulating DRD2 and SST2 in pituitary tumor cells, and the interplay between FLNA, cofilin and receptors in regulating tumor cell motility. (A) FLNA stabilizes DRD2 expression by preventing its lysosomal degradation, and functions as scaffold in mediating DRD2 signal transduction. (B) DRD2 activates ROCK/LIMK/cofilin pathway, promoting an increase of cofilin phosphorylation (inactivation), with consequent reduction of cell migration and invasion. (C) FLNA interaction with SST2 is required for SST2 clusters formation and alignment along actin fibers, prevents SST2 lysosomal degradation upon agonist challenge and functions as scaffold for inhibitory G proteins allowing SST2 signal transduction. Activated SST2 recruits a protein complex that includes FLNA, RhoA, ROCK, LIMK and cofilin, promoting cofilin phosphorylation and a consequent inhibition of cell migration. (D) FLNA phosphorylation regulates SST2 signal transduction. cAMP/PKA pathway activation induces FLNA phosphorylation. P-FLNA constitutively binds SST2, and hampers its coupling with inhibitory G proteins after agonist activation. SST2, when bound to dephosphorylated FLNA, inhibits adenyl cyclase activity, with a consequent reduction of PKA-mediated FLNA phosphorylation.
with a role for FLNA in the control of DRD2 fate after endocytosis, it has been shown in HEK293 cells that FLNA regulates DRD2 internalization and recycling (Zheng et al. 2016).

These data support the notion that FLNA is a trafficking adaptor, which allows an efficient recycling of GPCRs, as also showed for chemokine receptor CCR2 and β2-adrenergic receptor (Pons et al. 2017), and a protection against degradation, as demonstrated for calcium-sensing receptor (Zhang & Breitwieser 2005), calcitonin receptor (Seck et al. 2003), cystic fibrosis transmembrane conductance regulator (Thelin et al. 2007) and FcgammaRI (Beekman et al. 2008).

However, the role of FLNA in DRD2 regulation is not limited to guarantee the appropriate levels of the receptor on the plasma membrane, but extends to a scaffold function that enable DRD2 signal transduction. The work of Peverelli et al. demonstrated that in primary cultured human PRL-secreting cells, FLNA silencing prevented the inhibitory effects of DRD2 on PRL secretion and ERK1/2 phosphorylation (Peverelli et al. 2012). On the other hand, DA-resistant prolactinoma cells transfected with FLNA become able to respond to dopaminergic drugs (Peverelli et al. 2012).

Due to this function of FLNA in DRD2 expression and signaling in lactotrophs, the loss of FLNA expression may be one of the mechanisms involved in resistance of prolactinomas to dopaminergic drugs. Overall, these data reveal FLNA as a novel potential target to modulate the amount of active DRD2 at the cell membrane in PRL-secreting pituitary tumor cells (Fig. 2).

**FLNA role in GH-secreting tumor responsiveness to SSAs**

In GH-secreting tumors, SSTR2 is the main target of pharmacological expression with tumor response to medical therapy with SSA is well documented in literature, but resistance to SSAs has been observed also in the presence of SSTR2, suggesting post-receptor mechanisms involved (revised in Peverelli et al. 2015, Gadelta et al. 2017, Paragliola et al. 2017, Marazuela et al. 2018). The efficacy of SSA can be reduced due to an altered expression of beta arrestins, scaffold proteins involved both in desensitization and signal transduction of several GPCRs, including SSTRs (Tullipano et al. 2004, Peverelli et al. 2008). Indeed, low expression of beta arrestin 1, but not beta arrestin 2, correlated with a reduced recycling rate of SSTR2 and a better biochemical response to SSA, both in vitro and in vivo (Gatto et al. 2013). Alterations in SSTRs signal transduction might be due to aryl hydrocarbon receptor-interacting protein (AIP) tumor-suppressor gene mutations (Daly et al. 2010), typically correlating with octreotide resistance (Ibañez-Costa & Korbonits 2017). Moreover, tumor resistance has been associated with alterations of the expression of Raf kinase inhibitory protein, which regulates MAPK signaling, a pathway involved in mediating the antiproliferative effects of somatostatin (Fougnier et al. 2008).

Recently, a role for FLNA in both SSTR2 expression after prolonged agonist stimulation and signal transduction has been described. FLNA can directly bind SSTR2 first intracellular loop by its repeats 19–20 (Najib et al. 2012) (Fig. 1). In GH-secreting tumors tissues, FLNA protein is expressed at variable levels, with no correlation with SSTR2 expression (Peverelli et al. 2014), in striking contrast with DRD2 in prolactinomas (Peverelli et al. 2012). In addition, FLNA is not required for a proper localization of SSTR2 on the plasma membrane. Indeed, FLNA silencing in primary cultures of somatotropinomas does not affect SSTR2 intracellular localization on the plasma membrane neither its expression levels (Peverelli et al. 2014), in agreement with the evidence that in melanoma cell lines SSTR2 membrane localization does not depend on the presence of FLNA (Najib et al. 2012).

At higher level of detail, single-molecule microscopy analysis recently showed that dynamic SSTR2–FLNA interactions control SSTR2 spatial arrangement and mobility at the plasma membrane and are required for the formation of SSTR2 clusters and their alignment along actin fibers in CHO cells (Treppiedi et al. 2018). In addition, the transfection of a dominant negative FLNA fragment (FLNA 19–20), which prevents FLNA–SSTR2 binding (Peverelli et al. 2014), impaired the coupling of SSTR2 clusters to clathrin-coated pits, with a consequent decrease of SSTR2 internalization (Treppiedi et al. 2018) (Fig. 3).

A role for FLNA in dictating the fate of agonist-activated SSTR2, in analogy with DRD2, is supported by the observation that in GH-secreting pituitary tumor cells SSTR2–FLNA interaction is required to prevent activated SSTR2 lysosomal degradation and to maintain SSTR2 stability after prolonged agonist stimulation (Peverelli et al. 2014).

At the same time, FLNA is required for SSTR2 signal transduction. In human GH-secreting tumor primary cultured cells, FLNA silencing prevented SSTR2-induced reduction of cyclin D1 and activation of caspase 3/7, required for the antiproliferative and pro-apoptotic effects of SSTR2 (Peverelli et al. 2014). The FLNA
scaffold domain involving repeats 21–24 seems to play a paramount role in facilitating SSTR2 signaling. Indeed, overexpression of dominant negative mutant FLNA 21–24, that does not abolish the interaction of SSTR2 with endogenous FLNA, eliminated SSTR2 effects on apoptosis and ERK1/2 inhibition. These data suggest that the FLNA scaffold properties are required for the recruitment of signal transduction complexes to activated SSTR2. Another mechanism by which FLNA mediates SSTR2 antiproliferative action has been demonstrated in pancreatic neuroendocrine tumors, where a competition of FLNA with PI3K regulatory subunit p85 for the binding to SSTR2 occurs (Najib et al. 2012), and where FLNA is required for SSTR2 expression and signaling (Vitali et al. 2016). FLNA is also required to mediate the inhibitory effects of SSTR2 on cell migration and invasion in GH-secreting pituitary tumors (Peverelli et al. 2018a), by mediating the recruitment to activated SSTR2 of components of the cofilin pathway, as discussed below.

Altogether, these data support the idea that FLNA functions as a molecular platform able to connect SSTR2 with components of the machinery of intracellular trafficking and of the signal transduction cascade (Fig. 2).

Thus, low levels of FLNA in GH-secreting pituitary tumors, by causing loss of coupling of SSTR2 with downstream signal transduction molecules, might cause loss of responsivity of the patient to SS analogs even if in the presence of appropriate levels of SSTR2. Further studies in a large series of patients are required to investigate a possible correlation between FLNA expression levels and clinical behavior of GH-secreting tumors.

Despite the amino acidic sequence of SSTR2 required for FLNA binding is conserved in SSTR5, no data are found in literature about a FLNA role in regulating SSTR5.

This receptor subtype is highly expressed in GH-secreting tumors and is the most expressed SSTRs in ACTH-secreting tumors. Since the multi-ligand SSA pasireotide represents the only pituitary-directed drug approved by regulatory authorities to treat Cushing’s disease, at least in Europe, it would be of great interest to evaluate a possible FLNA role in molecular mechanisms underlying the resistance to pasireotide, occurring in 50–70% of patients with Cushing’s disease (Guelho & Grossman 2015).

Cytoskeleton role in pituitary tumors invasiveness

Cofilin promotes NFPT invasiveness and is regulated by DRD2

Non-functioning pituitary tumors (NFPTs) frequently show local invasiveness that strongly reduces the success of transsphenoidal neurosurgery, the treatment of choice for this type of tumor, and increases the incidence of tumor recurrence (Meiji et al. 2002, Losa et al. 2008). No diagnostic molecular markers predictive of the invasive behavior and recurrence of NFPTs are available. Moreover, the molecular mechanisms underlying the invasive behavior of these mostly benign tumors are unknown.

Overexpression of cofilin has been associated with tumor cell proliferation, invasion and metastasis in astrocytoma (Nagai et al. 2011), breast (Wang et al. 2006, Zhang & Tong 2010), colon (Popow-Woźniak et al. 2012), pancreatic (Wang et al. 2015), prostate (Collazo et al. 2014) and gallbladder (Yang et al. 2013) tumors, and cofilin dephosphorylation was observed in human malignant cells (Nagai et al. 2011).
A role for coflin in promoting invasion of NFPTs has recently been demonstrated. Peverelli et al. showed that overexpression of coflin induced an increase of cell migration of human non-functioning pituitary tumor HP75 cells, an effect reproduced by the constitutively active coflin phosphodeficient mutant S3A, but not phosphomimetic S3D (Peverelli et al. 2016). Moreover, the pro-migratory effect of active S3A coflin was supported by its intracellular co-localization with F-actin in membrane protrusions in HP75 cells, in contrast to S3D coflin, which is diffusely distributed in the cytoplasm.

These in vitro data are well supported by the analysis of coflin phosphorylation in human NFPT tissues. Indeed, Western blot analysis demonstrated higher phosphorylated coflin (P-cofilin)/total coflin ratio in non-invasive than in invasive NFPTs, and immunohistochemistry analysis showed a low or absent P-cofilin staining in invasive tumors, in contrast with high immunoreactivity for P-cofilin found in non-invasive tumors (Peverelli et al. 2016). From these experiments, coflin emerges as a potential new biomarker predictive of NFPTs invasiveness and recurrence, which could provide additional information for prognosis influencing the management of patients and the use of adjuvant therapies.

DRD2 is expressed in most NFPTs (Vieira Neto et al. 2015) but medical therapy with DRD2 agonists is still under debate (Delgado-López et al. 2018). Beside antiproliferative activity (Colao et al. 2000, Florio et al. 2008, Peverelli et al. 2010, Gagliano et al. 2013), DRD2 was recently demonstrated able to exert anti-migratory and anti-invasive activity in cultured cells from NFPTs and HP75 cells (Peverelli et al. 2016). This unprecedented effect of DRD2 in a tumor cell model is a consequence of the DRD2 ability to modify the intracellular pool of P-cofilin. Indeed, in these cells, DRD2 agonist promoted a Rho-associated protein kinase ROCK-dependent LIMK phosphorylation, which in turn induced coflin phosphorylation (Fig. 2). To date, DRD2 coupling with RhoA/ROCK signaling pathway has been described only in mouse striatal neurons (Deyts et al. 2009, Galan-Rodríguez et al. 2017), but the molecular mechanism involved has never been investigated. As described below, FLNA may function as scaffold linking together GPCRs and components of the coflin pathway (Peverelli et al. 2018a), suggesting that DRD2 effect on P-cofilin may be mediated by FLNA. However, G proteins coupled to DRD2, or beta arrestins, involved in DRD2 internalization (Kim et al. 2001) and able to activate Rho (Barnes et al. 2005, Ma et al. 2012), may be potential molecular players connecting DRD2 to coflin pathway.

These data first suggest a new role for DRD2 agonists in the control of invasive properties of NFPTs. Indeed, DRD2 actively participates in actin fibers remodeling by controlling coflin activation, with important consequences on cell migration and invasion.

Despite DRD2 being the main target of PRL-secreting tumors therapy, no data about DRD2 agonists effects on invasion and coflin phosphorylation in prolactinomas are available in literature. However, it was demonstrated that exposure of lactotrophs to dopamine stabilized the cortical actin cytoskeleton (Carbajal & Vitale 1997), consistently with an increase of P-cofilin.

Finally, the recent observation that the coupling of DRD2 to RhoA/ROCK pathway is specific of the short spliced version of the receptor (D2S) (Galan-Rodríguez et al. 2017) deserves further considerations. This DRD2 isoform differs from the long one (D2L) for the loss of 29 amino acids in the third intracellular loop, resulting in different physiological functions. The differential expression of these two splice variants has been associated with the biological behavior of PRL-secreting tumors. Indeed, lower expression of D2S transcript correlated with resistance to dopaminergic drugs (Caccavelli et al. 1994, Wu et al. 2010) and tumor invasiveness (Wu et al. 2010), consistent with a reduced or absent coupling of D2L with coflin pathway.

**GH-secreting tumors invasiveness is regulated by SSTR2 through FLNA-mediated coflin inactivation**

Invasion of the cavernous sinus, reported in 20–50% of patients with GH-secreting tumors, represents a clinical issue since the outcomes of transsphenoidal surgery are less favorable for the lesions invading surrounding tissues (Sarkar et al. 2014, Anik et al. 2017).

Recently, an anti-migratory effect of SSTR2 in GH-secreting tumor cells has been discovered, in addition to its recognized antiproliferative and pro-apoptotic actions (Peverelli et al. 2018a). This previously unknown SSTR2 ability to actively participate to cytoskeleton remodeling is mediated by FLNA and coflin.

The specific SSTR2 agonist BIM23120 inhibited migration and invasion on collagen IV in both primary cultured cells from human GH-secreting tumors and GH3 cell line (Peverelli et al. 2018a). It is of clinical relevance noting that these effects are reproduced by the two SSAs used in the pharmacological therapy of pituitary tumors: octreotide, with high preferential binding affinity for SSTR2, and pasireotide, with a broader spectrum of affinity for different receptor subtypes and high binding affinity to SST5.
The investigation about the molecular machinery involved identified the RhoA/ROCK/cofilin pathway as a new intracellular signaling cascade activated by SSTR2 (Peverelli et al. 2018a). Indeed, in GH3 cells, selective SSTR2 activation by BIM23120 strongly activated RhoA and induced a ROCK-mediated increase of P-cofilin/total cofilin ratio, which was required for the anti-invasive effects of SSTR2, in analogy with the mechanisms employed by DRD2 to reach the same effect in NFPT cells (Fig. 2).

In addition, the phosphorylation status of cofilin appeared to be an important regulator of GH-secreting tumor cells motility, since transfection of constitutively inactive phosphomimetic S3D cofilin was able to reduce GH3 cell invasion independently from SSTR2 activation, whereas no effect was observed after transfection of S3A or WT cofilin.

Thus, S3D cofilin functions in a dominant negative manner in this type of tumor, in line with the observation that it may compete with endogenous phosphorylated cofilin for binding to specific phosphatases, with a consequent increase of cofilin phosphorylation status (Chua et al. 2003).

The effects of overexpression of active S3A cofilin depend on the cell line. Indeed, S3A cofilin increased NFPT, but not GH-secreting, cell invasion (Peverelli et al. 2016, 2018a), supporting the hypothesis that multiple, cell-specific mechanisms, other than phosphorylation, are required to control the initial activation of cofilin (Song et al. 2006).

In line with the function of FLNA as scaffold for SSTR2 signal transduction molecules (Peverelli et al. 2014), the activation of cofilin pathway required FLNA, as demonstrated by both FLNA genetic silencing and transfection of FLNA dominant negative mutants preventing FLNA binding to SSTR2 (FLNA 19–20) or to signaling molecules (FLNA 21–24) (Peverelli et al. 2018a). Moreover, by confocal microscopy and coimmunoprecipitation assays, the authors demonstrated that upon agonist challenge SSTR2 colocalized with FLNA and cofilin at the plasma membrane, but cofilin recruitment to SSTR2 was completely lost in cells silenced for FLNA.

These data suggest that activated SSTR2 recruits a macromolecular complex that through FLNA anchors SSTR2 to actin fibers and connects molecular components of the cofilin pathway, enabling a direct effect of SSTR2 on actin cytoskeleton dynamics (Fig. 2).

Intriguingly, the overexpression of FLNA19–20 and 21–24 in GH3 cells reduced cell invasion, independently from SSTR2 selective stimulation, first revealing a role of these peptides as inhibitors of tumor cell invasiveness (Peverelli et al. 2018a).

The molecular mechanism involved might be related to the ability of FLNA to bind molecules that participate in the regulation of cell adhesion and migration processes. Indeed, the FLNA regions contained in both these dominant negative mutants are required for cell spreading and initiation of cell migration (Baldassarre et al. 2009) and integrin binding (Kiema et al. 2006, Ithychanda et al. 2009).

Mechanisms regulating FLNA expression and function in pituitary tumors

FLNA expression

The molecular events responsible for a low or absent FLNA expression in pituitary tumors remain an open question. A possible role for epigenetic silencing has been ruled out, at least in PRL-secreting tumors, since no methylation in the FLNA promoter regions was found neither in FLNA expressing nor in non-expressing prolactinomas (Peverelli et al. 2012).

Despite several germline FLNA mutations that lead to reduced or absent FLNA expression have been identified in human disease (see below), a possible presence of FLNA somatic mutations in pituitary tumors has never been investigated.

FLNA degradation is promoted by ubiquitination triggered by ASB2 proteins, subunits of E3 ubiquitin ligase complexes (Razinia et al. 2011). No data about FLNA ubiquitination and degradation process in pituitary tumors are available, but it is of interest to note that alterations of ubiquitin system due to somatic mutations of ubiquitin-specific peptidase 8 (USP8) gene play a pathogenetic role in the development of ACTH-secreting pituitary tumors (Reincke et al. 2015).

FLNA splicing variants

It is known that FLNA mRNA is subjected to alternative splicing. Among the described splice variants, of interest is the FLNA splice variant-1 (var-1), containing an internal deletion of 41 amino acids between C-terminal part of repeat 19 and the N-terminal part of repeat 20 (residues 2127–2167) (Pentikäinen et al. 2011) (Fig. 1). This deletion increased FLNA/integrins binding compared with nonspliced FLNA (van der Flier et al. 2002), suggesting a general role for this alternative splicing in regulating
FLNA binding to its interaction partners. Since FLNA regions that directly interact with SSTR2 and DRD2 are located in repeats 19–20, an altered binding of FLNA var-1 to these receptors can be hypothesized. Moreover, it is worth noting that the aminoacids residues spliced out in FLNA var-1 include serine 2152, target of phosphorylation (see below), and the putative NLS (2146–2149), with possible important implications for FLNA functions.

FLNA var-1 is widely expressed at low levels, but up to now no data about the expression of this variant in normal and tumoral pituitary is known. It is possible to hypothesize that the alternative splicing of FLNA may have implications in pituitary tumors responsiveness to SSAs and DRD2 agonists.

Mutations in FLNs splice sites have been previously associated with human diseases, such as PVNH (Oegema et al. 2013) and dilated cardiomyopathy (Begay et al. 2016), involving FLNA and FLNC, respectively.

**FLNA phosphorylation**

FLNA is target of phosphorylation of different kinases, such as PKA, PKC, CaM-kinase II, Pak1 (p21-activated kinase 1), RSK (ribosomal S6 kinase) and cyclin B1/Cdk1 (Chen & Stracher 1989, Jay et al. 2004, Woo et al. 2004, Cukier et al. 2007, Zhang et al. 2012, Hammer et al. 2013).


The N-terminal region of FLNA contains a PKA site probably involved in F-actin interaction (Jay & Stracher 1994), whereas the only PKA phosphorylation site in the C-terminal region of FLNA is serine 2152 in the repeat 20 of FLNA (Jay et al. 2000) (Fig. 1). cAMP/PKA pathway activation induced FLNA phosphorylation at S2152 in different cell systems (Chen & Stracher 1989, Jay et al. 2000, 2004), and recently, the same effect has been reported in GH-secreting pituitary tumors.

Indeed, in both GH3 and GH4C1 cell lines and in primary cultured cells from GH-secreting pituitary tumors, forskolin increased, and SSTR2 agonist reduced, FLNA phosphorylation at S2152, with dramatic effects on FLNA binding to SSTR2 and SSTR2 signal transduction (Peverelli et al. 2018b) (Fig. 2). The authors demonstrated that the phosphomimetic S2152D FLNA mutant constitutively bound to SSTR2, but precluded inhibitory G proteins coupling to SSTR2, and completely abolished antiproliferative, pro-apoptotic and anti-migratory effects of selective SSTR2 activation by BIM23120 (Fig. 2) (Peverelli et al. 2018b). In this scenario, phosphorylation seems to be a mechanism to switch FLNA function from a scaffold that allows SSTR2 signal transduction, to a signal termination protein that hampers all SSTR2 antitumoral effects (Fig. 2).

In a broader perspective, further studies are needed to investigate whether this mechanism may control the activity of other GPCRs that bind FLNA. In the field of pituitary tumors, the study of the FLNA phosphorylation offers new insights into the molecular determinants underlying SSA resistance of pituitary tumors and suggests phosphorylated FLNA as a novel biomarker predicting GH-secreting tumor responsiveness to SSA.

**Conclusions**

Cell cytoskeleton proteins, clearly far from being only structural cell components, are critically involved in the complex molecular machinery that determines the biological behavior of pituitary tumors. In particular, the multifunctional protein FLNA appears to be a molecular platform that by facilitating the interplay with several partners orchestrates DRD2 and SSTR2 expression, localization, internalization, intracellular trafficking, signal transduction and signal termination.

Therefore, its proper function is a mandatory requirement for the antitumoral action of dopaminergic and somatostatinergic drugs in pituitary tumors.

The biological responses to these currently used drugs do not only include the well-established inhibitory effects on hormone secretion and tumor growth, but also include the ability to restraint tumoral cell migration and invasion. It is not surprising that FLNA acts as an intermediary between the receptors of these drugs on the cell surface and the actin filaments of the cell cytoskeleton, also allowing the recruitment of the components of the pathway of cofolin, a protein specifically involved in actin filaments remodeling.

In this scenario, further studies aimed to deeply investigate the mechanisms of regulation of FLNA and cofolin might suggest new pharmacological strategies for DA or SSA resistant and invasive pituitary tumors. One important direction for future studies is to determine a possible crosstalk between the different cytoskeletal...
components identified as crucial in pituitary biology, including FLNA, actin, coflin, keratins and E-cadherin.

Understanding the molecular basis underlying the different biological behaviors of pituitary tumors will be a key milestone in reaching a personalized approach to treatment of this disease.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This study was supported by AIRC (Associazione Italiana Ricerca Cancro) grant to G M (IG 2017-20594), a Pfizer grant to E P (WI219094), Ricerca Corrente Funds from the Italian Ministry of Health and Progetti di Ricerca di Interesse Nazionale (PRIN) grant to G M (2015ZHKFTA).

References


Hammer A, Rider, L, Odalmeije, P, Cook, L, Qi, Q, Mattingly, RR & Diakonova M 2013 Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolatin through filamin A. Molecular Endocrinology 27 455–465. (https://doi.org/10.1210/me.2012-1291)

Han, L, Stope MB, de Jesús ML, Ouwe Weerink PA, Urban, M, Wieland, T, Rosskopf, D, Mizuno, K, Jakobs, KH & Schmidt M 2007 Direct stimulation of receptor-controlled phospholipase D1 by phospho-CAK. EMBO Journal 26 4189–4202. (https://doi.org/10.1038/s.embol.7601852)


Lin R, Karpa K, Kabhani N, Goldman-Rakic P & Levenson R 2001 Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. PNAS 98: 5258–5263. (https://doi.org/10.1073/pnas.011538198)


Cytoskeleton in pituitary


Seck T, Baron R & Horne WC 2003 Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. Journal of Biological Chemistry 278 10408–10416. (https://doi.org/10.1074/jbc.M209655200)


Zhang Y & Tong X 2010 Expression of the actin-binding proteins indicates that coflin and fascin are related to breast tumour size. *Journal of International Medical Research* **38** 1042–1048. (https://doi.org/10.1177/147323001003800331)


Received in final form 14 November 2018
Accepted 4 December 2018